Therapeutic targeting of PP2A

Caitlin M. O'Connor, Abbey Perl, Daniel Leonard, Jaya Sangodkar, Goutham Narla

Research output: Contribution to journalReview articlepeer-review

145 Scopus citations

Abstract

Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase that regulates many cellular processes. Given the central role of PP2A in regulating diverse biological functions and its dysregulation in many diseases, including cancer, PP2A directed therapeutics have become of great interest. The main approaches leveraged thus far can be categorized as follows: 1) inhibiting endogenous inhibitors of PP2A, 2) targeted disruption of post translational modifications on PP2A subunits, or 3) direct targeting of PP2A. Additional insight into the structural, molecular, and biological framework driving the efficacy of these therapeutic strategies will provide a foundation for the refinement and development of novel and clinically tractable PP2A targeted therapies.

Original languageEnglish
Pages (from-to)182-193
Number of pages12
JournalInternational Journal of Biochemistry and Cell Biology
Volume96
DOIs
StatePublished - Mar 2018

Keywords

  • ABL-127
  • Bortezomib
  • CIP2A
  • Cancer
  • Celastrol
  • Cell signaling
  • Drug development
  • Erlotinib
  • FTY720
  • LB-100
  • LCMT-1
  • OP449
  • PME-1
  • PP2A
  • Phenothiazines
  • Protein phosphatase 2A
  • Protein phosphatases
  • SET
  • SMAPs
  • Tumor suppressors

Fingerprint

Dive into the research topics of 'Therapeutic targeting of PP2A'. Together they form a unique fingerprint.

Cite this